

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-A₂-Glycoprotein Levels in Patients with Type 2 Diabetes

Xin Liao^{1*}, Xuemei Wang^{1*}, Haopeng Li^{1*}, Ling Li³, Guohao Zhang^{1,4}, Mengliu Yang², Lei Yuan², Hua Liu⁵, Gangyi Yang^{1,2§}, Lin Gao^{1§}

¹Department of Endocrinology, the Affiliated Hospital, Zunyi Medical University, 563003 Guizhou, China

²Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, 400010 Chongqing, China

³Key Laboratory of Diagnostic Medicine (Ministry of Education) and Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing Medical University, 400016, China

⁴Staff Hospital of Guizhou Maotal Mistillery Group Company, Renhual, 564500, Guizhou, China


⁵Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi 39216

*These authors contributed equally to this project.

§Correspondence: Department of Endocrinology, Zunyi Medical University, Guizhou, China

Tel: +0851-28608213; Fax: 0851-28608213.

Email: gaolinpro@yeah.net; gangyiyang@163.com.



Supplemental Figure 1. The effects of DAPA on PPAR- α and SREBP-1c expression *in vitro*.

HepG2 cells were treated with 4 μ M DAPA with or without GW9662 for 24 h. Cell lysates were collected for mRNA or protein assay. (A) PPAR- α mRNA expression. (B) PPAR- α protein expression. (C) SREBP-1c mRNA expression. The results represent three separate experiments performed in duplicates as means \pm SEM. * $P < 0.05$, ** $P < 0.01$.

Supplemental Table 1 Primer sequences for quantitative Real-Time PCR assays

Gene	Primer Sequences
ZAG (human)	Forward: CTTGGCTCACTCAATGACCTC Reverse: CTCCGCTGCTTCTGTTATTC
ADI (human)	Forward: GCCTACCACATCACAGTC Reverse: TCAGCATAGAGTCCATTACG
FAS (human)	Forward: GTCCACCAGCAACATCAG Reverse: TTCTCCAGCAAGCCATCT
ACC (human)	Forward: AACCACATCTTCCTCAACTT Reverse: ACTTCCATACCGCATTACC
HSL (human)	Forward: TTGAGATGCCACTGACTG Reverse: CACTGTCCTGTCCTTCAC
TNF- α (human)	Forward: CTCCTCACCCACACCATCAGCCGCA Reverse: ATAGATGGGCTCATACCAGGGCTTG
TNF-A (mouse)	Forward: GTGGAAGTGGCAGAAGAG Reverse: TAGACAGAAGAGCGTGGT
IL-6 (human)	Forward: AAATTCGGTACATCCTCGACGG Reverse: GGAAGGTTCAAGTTGTTTTCTGC
IL-6 (mouse)	Forward: GGACCAAGACCATCCAATTC Reverse: ACCACAGTGAGGAATGTCCA
CRP (human)	Forward: TTCTCGTATGCCACCAAG Reverse: TTCTTCAGACTCTTCCTCAC
CRP (mouse)	Forward: CTACCAAGAAGAAGTCTAACG Reverse: CAATCCAGAAGTCTACAATCC
PPAR- γ (human)	Forward: ACTCCACATTACGAAGACAT Reverse: CTCCACAGACACGACATT
PPAR- α (human)	Forward: ACCACCATTCCCACAGACAG Reverse: CCAGGTTTGCGTAGAAGAGC
SREBP-1c (human)	Forward: GAGAAGCACCAAGGAGACGA Reverse: TTCCCAGCCCCTCAGATAC

ZAG, Zinc- α_2 -Glycoprotein; ADI, adiponectin; FAS, fatty acid synthase; ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase; TNF- α , tumour necrosis factor- α ; IL-6, interleukin-6; CRP, C-reactive protein; PPAR γ , Peroxisome proliferator activated receptor γ ; PPAR- α , Peroxisome proliferator activated receptor α ; SREBP-1c, sterol regulatory element-binding protein-1c